Eli Lilly And Co (LLY) Rating Reiterated by Cantor Fitzgerald

Eli Lilly And Co (NYSE:LLY)‘s stock had its “buy” rating reiterated by analysts at Cantor Fitzgerald in a research note issued on Monday.

The analysts wrote, “The growth prospects for LLY’s key drugs — Verzenio — as well as its pipeline assets, especially in pain, are underappreciated, in our view. Valuation Summary We use a blend of DCF and EV/EBITDA analysis to arrive at our 12-month PT of $128. The Disclosure Section may be found on pages 3 – 4.Valuation We use a blend of DCF and EV/EBITDA analysis to arrive at our 12-month PT of $128. Risks Greater-than-expected brand and/or generic competition for Lilly’s key drugs/products.””

Other equities analysts have also recently issued research reports about the stock. Zacks Investment Research raised shares of Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $129.00 target price on the stock in a research note on Tuesday, October 9th. Guggenheim began coverage on shares of Eli Lilly And Co in a research note on Monday, October 8th. They set a “buy” rating on the stock. Credit Suisse Group raised shares of Eli Lilly And Co from an “underperform” rating to a “neutral” rating in a research note on Wednesday, October 31st. Barclays raised their target price on shares of Eli Lilly And Co from $112.00 to $120.00 and gave the company an “overweight” rating in a research note on Friday, October 12th. Finally, ValuEngine raised shares of Eli Lilly And Co from a “hold” rating to a “buy” rating in a research note on Monday, October 8th. Ten investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $113.24.

Eli Lilly And Co stock opened at $120.43 on Monday. The stock has a market cap of $128.06 billion, a price-to-earnings ratio of 28.14, a P/E/G ratio of 1.85 and a beta of 0.37. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.53 and a current ratio of 1.91. Eli Lilly And Co has a 52 week low of $73.69 and a 52 week high of $121.84.

Eli Lilly And Co (NYSE:LLY) last released its earnings results on Tuesday, November 6th. The company reported $1.39 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.35 by $0.04. The firm had revenue of $6.06 billion for the quarter, compared to analysts’ expectations of $6.04 billion. Eli Lilly And Co had a net margin of 1.85% and a return on equity of 42.84%. Eli Lilly And Co’s quarterly revenue was up 7.1% on a year-over-year basis. During the same quarter last year, the company earned $1.05 EPS. As a group, research analysts forecast that Eli Lilly And Co will post 5.58 earnings per share for the current year.

In other news, SVP Alfonso G. Zulueta sold 4,000 shares of the firm’s stock in a transaction dated Thursday, January 31st. The shares were sold at an average price of $120.00, for a total transaction of $480,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Myles O’neill sold 25,000 shares of the firm’s stock in a transaction dated Monday, December 10th. The shares were sold at an average price of $112.92, for a total transaction of $2,823,000.00. Following the transaction, the senior vice president now owns 26,562 shares of the company’s stock, valued at approximately $2,999,381.04. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,020,383 shares of company stock valued at $117,579,574. Insiders own 0.11% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in the business. First Personal Financial Services boosted its holdings in shares of Eli Lilly And Co by 2.3% in the fourth quarter. First Personal Financial Services now owns 3,931 shares of the company’s stock worth $455,000 after buying an additional 89 shares during the period. Carroll Financial Associates Inc. boosted its holdings in shares of Eli Lilly And Co by 1.3% in the fourth quarter. Carroll Financial Associates Inc. now owns 7,029 shares of the company’s stock worth $810,000 after buying an additional 91 shares during the period. Bailard Inc. boosted its holdings in shares of Eli Lilly And Co by 3.6% in the fourth quarter. Bailard Inc. now owns 2,672 shares of the company’s stock worth $309,000 after buying an additional 92 shares during the period. Wesbanco Bank Inc. boosted its holdings in shares of Eli Lilly And Co by 0.4% in the fourth quarter. Wesbanco Bank Inc. now owns 26,542 shares of the company’s stock worth $3,071,000 after buying an additional 95 shares during the period. Finally, Partnervest Advisory Services LLC boosted its holdings in shares of Eli Lilly And Co by 1.4% in the fourth quarter. Partnervest Advisory Services LLC now owns 6,787 shares of the company’s stock worth $785,000 after buying an additional 96 shares during the period. Institutional investors own 76.89% of the company’s stock.

About Eli Lilly And Co

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Article: Why are analyst ratings important in trading stocks?

Analyst Recommendations for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply